PTC THERAPEUTICS, INC. — Form 10-Q
Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Matthew B. Klein (CEO) and Pierre Gravier (CFO) issued standard Sarbanes-Oxley certifications on July 30, 2026 for the Q2 2026 10-Q (period ended June 30, 2026). Both officers certified that the report complies with SEC requirements, contains no material misstatements, and fairly presents financial condition and results. Neither officer disclosed any material weaknesses or significant deficiencies in internal controls or fraud involving management.
Why this rating
Routine SOX certification with no adverse control findings. Standard disclosure; no material changes or events indicated.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.